Cipla receives EIR from USFDA for API facility in Bengaluru

23 Sep 2019 Evaluate

Cipla has received the Establishment Inspection Report (EIR), indicating closure of the inspection from United States Food and Drug Administration (USFDA). The agency had conducted inspection at API manufacturing facility in Virgonagar, Bengaluru, from July 15-19, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1405.40 6.60 (0.47%)
25-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.55
Dr. Reddys Lab 6217.15
Cipla 1405.40
Zydus Lifesciences 953.50
Lupin 1589.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.